Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02793700 · ClinicalTrials.gov registry record

Pharmacokinetics (PK) and Modeling of Betamethasone Therapy in Threatened Preterm Birth

A clinical trial of Premature Labor, sponsored by Indiana University.

Completed
Registry status
210
Enrollment target
2
Study locations

NCT02793700 is a study of Premature Labor that has completed, run by Indiana University. The registered enrollment target is 210 participants. The trial reports 2 study locations across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02793700, a study of Premature Labor, has completed, sponsored by Indiana University.

COMPLETED
Registry status
210 participants
Enrollment target
2
Study locations

Study Summary

Respiratory distress syndrome (RDS) is a life-threatening condition for premature neonates. Antenatal glucocorticoids have been used clinically in women with threatened preterm birth to accelerate lung maturation for more than 40 years. The current treatment strategy for women with threatened preterm delivery is for a standard, "one size fits all" dosing with either betamethasone (BMZ) or dexamethasone. It is well known that pregnancy introduces additional variability in response to medication therapy with different physiological changes and alterations in the activity of drug metabolizing enzymes. The objective of this project is to evaluate the pharmacokinetic (PK), pharmacodynamic, and pharmacogenetic parameters of betamethasone (BMZ) and determine the differences in response and benefit in pregnancy. An individualized dosing approach to medications in pregnancy, such as BMZ, is crucial to optimize efficacy of this important medication.

Conditions Studied

Study Locations (2)

Indiana

  • Eskenazi Hospital - Indianapolis
  • IUH Methodist Hospital - Indianapolis

Trial Details

FieldValue
Enrollment Target 210 participants
Start Date 2016-07
Est. Completion 2022-03

Sponsor

Indiana University

890 total trials

What the Registry Record Tells You About NCT02793700

The ClinicalTrials.gov registry entry for NCT02793700 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 210 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Indiana University, which has 890 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Premature Labor appearing as the primary indexed condition, and to 0 interventions.

NCT02793700 reports 2 study locations spanning 1 distinct geographic area - top geographies include Indiana.

Frequently Asked Questions

What is clinical trial NCT02793700 about?

NCT02793700 is a clinical study titled "Pharmacokinetics (PK) and Modeling of Betamethasone Therapy in Threatened Preterm Birth". Respiratory distress syndrome (RDS) is a life-threatening condition for premature neonates. Antenatal glucocorticoids have been used clinically in women with threatened preterm birth to accelerate lung maturation for more than 40 years. The current treatment strategy for women with threatened preter...

What is the current status of trial NCT02793700?

This trial is currently completed. The enrollment target is 210 participants. The study started on 2016-07. Estimated completion is 2022-03.

What conditions does trial NCT02793700 study?

This clinical trial studies the following conditions: Premature Labor.

Who is sponsoring clinical trial NCT02793700?

This trial is sponsored by Indiana University, which has 890 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT02793700 being conducted?

This trial has 2 study locations across Indiana. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Premature Labor

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.